About RiboTargets
RiboTargets is a Healthcare company based in Abington (United States) founded in 1997, and was acquired by Vernalis in October 2003. Small molecule therapeutics against cancer and infectious diseases. RiboTargets offers products and services including Identity Theft Resources and Blog Content. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral. Its competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines; 3 of its 3 listed competitors have raised funding.
Company details
As of April 23, 2003, RiboTargets Holdings plc was acquired by British Biotech plc. RiboTargets Holdings plc, a biotechnology company, engages in the discovery and development of small molecule therapeutics addressing areas of medical need in infection and cancer treatment. Its research and development is focused on protein targets for new cancer therapies and anti-infective therapies. RiboTargets technology is focused on the interactions between RNA and its regulatory proteins, such as those that attach ribosomes before translation, or move RNA around the cell. The company also has developed three-dimensional computer simulations of RNA binding sites to find small molecules with the correct structure to be specific.
- Headquarters Abington, United States
- Stage Acquired
- SectorsHealthcare
- Website ribotargets.com
- Acquired by Vernalis (Oct 2003)
Products & Services of RiboTargets
RiboTargets offers a comprehensive portfolio of products and services, including Identity Theft Resources and Blog Content.
Provides articles and tips on preventing identity theft
Delivers posts on security and miscellaneous topics
Investors in RiboTargets
RiboTargets has secured backing from 1 investor. Prominent investors backing the company include Vernalis.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Vernalis is engaged in structure-based drug discovery collaborations. | 1999 | vernalis.com | Wokingham, United Kingdom |
Investor details for RiboTargets
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of RiboTargets
2 dated milestones of RiboTargets across 6 years, from founding to its latest funding, stage changes and deals.
- Founded RiboTargets is founded.
- Exit Acquired by Vernalis.
Competitors of RiboTargets
RiboTargets has 3 listed competitors in our database, 3 of them funded. They include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| adaptivebiotech.com | 2009 | Seattle, United States | $419.15M | 609 | Clinical diagnostics and drug discovery for immune diseases are provided. | |
| generatebiomedicines.com | 2018 | Somerville, United States | $643M | 286 | Developer of novel protein-based therapeutics using machine learning and biological engineering |
Detailed competitors of RiboTargets
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
3 companies that operate in the same segment as RiboTargets (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about RiboTargets
RiboTargets was founded in 1997.
RiboTargets is headquartered in Abington, United States. It is registered at Abington, Massachusetts, United States.
As of April 23, 2003, RiboTargets Holdings plc was acquired by British Biotech plc. RiboTargets Holdings plc, a biotechnology company, engages in the discovery and development of small molecule therapeutics addressing areas of medical need in infection and cancer treatment. Its research and development is focused on protein targets for new cancer therapies and anti-infective therapies. RiboTargets technology is focused on the interactions between RNA and its regulatory proteins, such as those that attach ribosomes before translation, or move RNA around the cell. The company also has developed three-dimensional computer simulations of RNA binding sites to find small molecules with the correct structure to be specific.
RiboTargets's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
RiboTargets offers Identity Theft Resources and Blog Content.
RiboTargets has 1 investor. Key investors include Vernalis.
Yes. RiboTargets was acquired by Vernalis in October 2003.